Naveen Vasudev
@nav_vasudev
Followers
246
Following
901
Media
11
Statuses
103
Academic GU Medical Oncologist with a research interest in renal cell carcinoma
Leeds, England
Joined May 2017
💥 12- vs 3-weekly IPI in #RCC (PRISM). Just out @JCO_ASCO with extended FU Modified IPI (+nivo): • Significantly ⬇️ G3/4 toxicity ✅ • ORR 45%✅ • Comparable PFS/OS (32m FU)✅ https://t.co/R1btpKImSA
@tompowles1 @lisapic @DrSRBrown @Oncology_Doctor @LIMRLeeds
3
22
47
The weekly cancer MDT meeting can cause treatment delays, result in poor quality decisions, and waste clinicians’ time, say @tomroques and colleagues. It’s time for a fresh approach https://t.co/sN9CUmG5uH
bmj.com
Long meetings involving dozens of clinicians can delay patient care and leave no room for service improvement. It’s time for a fresh approach, say Tom Roques and colleagues For 30 years, multidisci...
15
60
160
Nivolumab and Ipilimumab for Metastatic Castration-Resistant #ProstateCancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study https://t.co/nD3NZmnFEB The NEPTUNES phase II trial assessed the efficacy of combination immunotherapy with nivolumab
0
24
50
Bio-miR study is already published! Our latest research article focused on predicting the risk of relapse in localized renal cell carcinoma through miRNA analysis is available at the @BrJCancer
https://t.co/Id3jCIT56n
0
11
20
A great day discussing #kidneycancer at the Ipsen Renal cancer education day in London! Great to see talks from @RickyFrazer1 @nav_vasudev @AlbigesL and so many more. A great day of kidney cancer👍and a lovely catch up.
0
3
8
Always great to see @mcgranjo777 and chat all things #RCC. Thanks John for dropping in to Leeds on your tour de north and for an, as always, fab talk! 🔥 @helendearden3
1
0
10
Come and work with us! New 3-year postdoc position in cancer immunology and transcriptomics funded by Cancer Research UK @CR_UK. Collaboration with @nav_vasudev and @TurajlicLab More info and apply: https://t.co/DCFyw4tkLC Closes 19 March! It’ll be fun! @HullYorkMed, @YBRI_UoY
0
9
6
Fully-funded PhD opening in our lab with @nanopore and @nav_vasudev in kidney cancer transcriptomics and immunology. It'll be fun! Closes Dec 13! https://t.co/WCJXJx2Gq3
findaphd.com
PhD Project - MRC DiMeN Doctoral Training Partnership: Exploring cancer transcriptomes with Nanopore long-read sequencing at University of York, listed on FindAPhD.com
0
4
6
#IUCS24 - fantastic meeting!! Privilege to take part and learn from amazing friends and colleagues in GU oncology. Many congrats @gbanna74 and @ravikanesvaran 🌟 @montypal @neerajaiims @achoud72 @mcgranjo777 @DrYukselUrun
1
3
30
Congrats @joshuacylee! Great work!
Our paper from @joshuacylee is out @genomeresearch! @nanopore #directRNA & #cDNA seq in #ccRCC. Cancer transcriptomes are way more complex than you think + new correlates of relapse + a novel PD-L1 isoform! https://t.co/b0UOjaHktU Thanks @Libby_Snell_, @nav_vasudev
1
0
7
📣 We are happy to announce that 🎓#IUCS24 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4.5 European CME credits (ECMEC®s)! Register now for free! 👉 https://t.co/EZdIo0GrnC
#urology #cancer
0
4
5
How to choose the best treatment sequencing for mRCC? Join us & discuss with @nav_vasudev from St James's University Hospital, Leeds in presence or virtually! Register for free➡️ https://t.co/tuyzBkWwcy
#IUCS24 #urology #oncology @gbanna74 @ravikanesvaran
0
7
13
🌟 Unmissable Opportunity for Urology and Oncology Professionals! 🌟 Join us for FREE at the Second International Urology Cancer Summit (IUCS @urologysummit) in Portsmouth on September 27, 2024. https://t.co/tdn19Pmm04
4
7
16
1/ Now out at @JCO_ASCO! Plasma KIM-1 (pKIM-1) helps predict benign vs malignant renal masses and is prognostic for clinical outcomes. https://t.co/m29YVHGKkr
3
23
67
What an honour to have none other than @drenriquegrande visit us in Leeds and present at our weekly education meeting. Fantastic talk from one of the greats….and turns out, he’s my twin 😃 @HelenDearden3
3
1
19
@ZaydTippu applying lessons learned from TracerX RCC @TurajlicLab with respect to evolutionary patterns in RCC in order to understand risk of recurrence after nephrectomy #IKCSEU24 @KidneyCancer
0
5
15
📣The Call for Abstract for #IUCS24 is now open! Don't miss the opportunity to be part of the Scientific Programme, to exchange your experiences and to showcase your research. 📆Submission deadline June 30, 2024. All info here 👉 https://t.co/tNwfjR22Di
#urology #cancer
1
8
9
New exciting PhD opportunity! Are you interested in cancer immunology and cutting-edge transcriptomics? Come and do an #iCASE #PhD with us in collaboration with Oxford @nanopore. Funding: @DiMeN_DTP @The_MRC. @HullYorkMed @YBRI_UoY @UniOfYork
https://t.co/KabXjIHVfc
findaphd.com
PhD Project - Exploring cancer transcriptomes with Nanopore long-read sequencing at University of York, listed on FindAPhD.com
0
7
8
Spacing out IPI is less toxic and looks as efficacious. These data mirror similar findings in melanoma and NSCLC. Huge team effort. Thank you to all the patients and their families, as well as the clinical study teams, who participated in this important trial!
0
1
10
Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023
22
485
1K